These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19925429)

  • 41. Genome-wide association studies in pharmacogenomics.
    Daly AK
    Nat Rev Genet; 2010 Apr; 11(4):241-6. PubMed ID: 20300088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insights from genome-wide association studies of drug response.
    Zhou K; Pearson ER
    Annu Rev Pharmacol Toxicol; 2013; 53():299-310. PubMed ID: 23072379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
    van Erp NP; Eechoute K; van der Veldt AA; Haanen JB; Reyners AK; Mathijssen RH; Boven E; van der Straaten T; Baak-Pablo RF; Wessels JA; Guchelaar HJ; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(26):4406-12. PubMed ID: 19667267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.
    Walko CM; McLeod H
    Nat Clin Pract Oncol; 2009 Mar; 6(3):153-62. PubMed ID: 19174777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic variation and association mapping for 12 agronomic traits in indica rice.
    Lu Q; Zhang M; Niu X; Wang S; Xu Q; Feng Y; Wang C; Deng H; Yuan X; Yu H; Wang Y; Wei X
    BMC Genomics; 2015 Dec; 16():1067. PubMed ID: 26673149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of genetic variation on late toxicities in childhood cancer survivors: A review.
    Clemens E; van der Kooi ALF; Broer L; van Dulmen-den Broeder E; Visscher H; Kremer L; Tissing W; Loonen J; Ronckers CM; Pluijm SMF; Neggers SJCMM; Zolk O; Langer T; Zehnhoff-Dinnesen AA; Wilson CL; Hudson MM; Carleton B; Laven JSE; Uitterlinden AG; van den Heuvel-Eibrink MM
    Crit Rev Oncol Hematol; 2018 Jun; 126():154-167. PubMed ID: 29759558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.
    Udagawa C; Zembutsu H
    Cancer Sci; 2020 Oct; 111(10):3445-3457. PubMed ID: 32780457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenetics in clinical dermatology.
    Ameen M; Smith CH; Barker JN
    Br J Dermatol; 2002 Jan; 146(1):2-6. PubMed ID: 11841360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PharmFrag: An Easy and Fast Multiplex Pharmacogenetics Assay to Simultaneously Analyze 9 Genetic Polymorphisms Involved in Response Variability of Anticancer Drugs.
    Bouvet R; Verdier MC; El Baroudi Y; Galibert MD; David V; Schutz S; Tron C
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity.
    Chan SL; Jin S; Loh M; Brunham LR
    Pharmacogenomics; 2015; 16(10):1161-78. PubMed ID: 25978008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigating the importance of individual mitochondrial genotype in susceptibility to drug-induced toxicity.
    Penman SL; Carter AS; Chadwick AE
    Biochem Soc Trans; 2020 Jun; 48(3):787-797. PubMed ID: 32453388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
    Giacomini KM; Yee SW; Mushiroda T; Weinshilboum RM; Ratain MJ; Kubo M
    Nat Rev Drug Discov; 2017 Jan; 16(1):1. PubMed ID: 27885282
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of genome-wide association studies for cancer research and drug repositioning.
    Zhang J; Jiang K; Lv L; Wang H; Shen Z; Gao Z; Wang B; Yang Y; Ye Y; Wang S
    PLoS One; 2015; 10(3):e0116477. PubMed ID: 25803826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.
    Trendowski MR; El Charif O; Dinh PC; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Feb; 25(4):1147-1155. PubMed ID: 30305294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs.
    Zhang Z; Wu Y; Tan NC; Jiang Y
    Epileptic Disord; 2019 Aug; 21(4):330-336. PubMed ID: 31403464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.
    Donnelly JG
    Ther Drug Monit; 2004 Apr; 26(2):231-5. PubMed ID: 15228171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of genetic factors on platinum-induced gastrointestinal toxicity.
    Zheng Y; Deng Z; Tang M; Xiao D; Cai P
    Mutat Res Rev Mutat Res; 2020; 786():108324. PubMed ID: 33339576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [State of the art of pharmacogenetic diagnostics in drug therapy].
    Kirchheiner J; Seeringer A; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Managing asthma in the 21st century: role of pharmacogenetics.
    Wechsler ME
    Pediatr Ann; 2006 Sep; 35(9):660-2, 664-9. PubMed ID: 16999299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.